Cartesian Therapeutics (NASDAQ:RNAC) Price Target Cut to $45.00
Cartesian Therapeutics (NASDAQ:RNAC – Free Report) had its price target decreased by HC Wainwright from $49.00 to $45.00 in a report published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. Several other analysts also recently weighed in on the company. Leerink Partnrs reiterated an outperform rating on shares of […]
More Stories
Royal Bank of Canada Issues Positive Forecast for Tidewater Renewables (TSE:LCFS) Stock Price
Tidewater Renewables (TSE:LCFS – Get Free Report) had its price objective hoisted by Royal Bank of Canada from C$5.00 to...
Golden Matrix Group Reports Preliminary Estimated Results, Shows Increase in Revenue for FY 2024On January 13, 2025, Golden Matrix Group (NASDAQ: GMGI) disclosed its preliminary estimated results of operations for the fiscal year ended December 31, 2
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Talbot Financial LLC Sells 195 Shares of Arthur J. Gallagher & Co. (NYSE:AJG)
Talbot Financial LLC cut its holdings in shares of Arthur J. Gallagher & Co. (NYSE:AJG – Free Report) by 0.6%...
Reinhart Partners LLC. Has $111.40 Million Stock Position in Frontdoor, Inc. (NASDAQ:FTDR)
Reinhart Partners LLC. lessened its stake in Frontdoor, Inc. (NASDAQ:FTDR – Free Report) by 10.5% in the fourth quarter, according...
BlackRock, Inc. (NYSE:BLK) Stock Position Reduced by Talbot Financial LLC
Talbot Financial LLC cut its stake in shares of BlackRock, Inc. (NYSE:BLK – Free Report) by 2.6% during the fourth...
Reinhart Partners LLC. Decreases Holdings in Fidelity National Information Services, Inc. (NYSE:FIS)
Reinhart Partners LLC. cut its stake in shares of Fidelity National Information Services, Inc. (NYSE:FIS – Free Report) by 17.8%...